SolasCure Shares Promising Study Results for Aurase Wound Gel

Study results show that SolasCure Ltd.’s Aurase Wound Gel (AWG) can achieve debridement without any additional pain to the patient.

The results are detailed in a peer-reviewed study in the International Wound Journal.¹ The paper reports findings from a Dose Escalation Study examining the use of tarumase, the enzymatic debridement agent in the company’s investigational AWG for treating venous leg ulcers (VLUs).

VLUs are painful, chronic wounds that require thorough debridement to support healing. However, existing methods of debridement are either slow and painless (autolytic), or more rapid and associated with significant pain (surgical and mechanical), often requiring anesthesia while some enzymatic treatments can also increase pain levels. The study explores tarumase, an enzyme originally isolated from medical maggots, which targets fibrin, collagen and elastin in wounds. AWG delivers tarumase in a proprietary hydrogel formulation, offering a gentle, patient-friendly alternative that enables effective debridement without adding to the patient’s pain burden.

Building on positive Phase IIA clinical findings, the study reinforces AWG’s favorable safety profile and supports its pain-free application.² Results show that AWG containing concentrations of tarumase up to 11 U/mL did not result in any increase in patient-reported pain above baseline, either shortly after application or after remaining on the wound for 48–72 hours. AWG is currently in Phase II clinical trials for the VLU treatment.

“This publication highlights AWG’s unique pain-free profile and patient-centric qualities, a key attribute that has, until now, been underrepresented,” SolasCure Senior Medical Advisor David Goldsmith said. “By emphasizing these differentiators, the study supports AWG’s significant potential to transform outcomes for patients with chronic wounds.”

SolasCure is a biologics company addressing the issue of inadequate debridement and healing solutions for chronic wounds. Its product, Aurase Wound Gel, addresses a significant unmet medical need: better wound bed preparation. Its approach incorporates biomimicry of medical maggots’ natural processes that clean wounds and promote healing. The Cambridge, U.K.-based firm aims to provide accessible solutions across all settings from hospital to home care. SolasCure was founded in 2017 as a spin-off from BRAIN Biotech AG, a German biotech company focused on harnessing biological diversity to develop innovative solutions.

References
¹ Goldsmith D, Fairlamb DM. The Potential Role for a Painless Enzymatic Debridement Gel in Wound Bed Preparation for Venous Leg Ulcers-A Dose Escalation Study. Int Wound J. 2025 Jun;22(6):e70702. doi: 10.1111/iwj.70702. PMID: 40512647; PMCID: PMC12164925.
² Fairlamb, D. M., Szepeshazi, K., Goldsmith, D., Danos, P., Lev-Tov, H., Young, N., Hanft, J., & Zelen, C. (2024). First clinical evaluation of the safety and efficacy of tarumase for the debridement of venous leg ulcers. International wound journal, 21(3), e14805. https://doi.org/10.1111/iwj.14805